Genmab A/S
GNMSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $96,544,059 | $139,216,863 | $194,137,658 | $166,955,736 |
| - Cash | $9,858,000 | $14,867,000 | $9,893,000 | $8,957,000 |
| + Debt | $1,029,000 | $770,000 | $597,000 | $425,000 |
| Enterprise Value | $87,715,059 | $125,119,863 | $184,841,658 | $158,423,736 |
| Revenue | $21,526,000 | $16,474,000 | $14,595,000 | $8,482,000 |
| % Growth | 30.7% | 12.9% | 72.1% | – |
| Gross Profit | $20,541,000 | $16,248,000 | $14,595,000 | $8,482,000 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| EBITDA | $9,697,000 | $5,991,000 | $7,328,000 | $4,179,000 |
| % Margin | 45% | 36.4% | 50.2% | 49.3% |
| Net Income | $7,844,000 | $4,352,000 | $5,452,000 | $2,957,000 |
| % Margin | 36.4% | 26.4% | 37.4% | 34.9% |
| EPS Diluted | 121.36 | 66.02 | 82.59 | 45.54 |
| % Growth | 83.8% | -20.1% | 81.4% | – |
| Operating Cash Flow | $7,771,000 | $7,380,000 | $3,912,000 | $2,228,000 |
| Capital Expenditures | -$187,000 | -$376,000 | -$317,000 | -$252,000 |
| Free Cash Flow | $7,584,000 | $7,004,000 | $3,595,000 | $1,976,000 |